Microbead-induced ocular hypertensive mouse model for screening and testing of aqueous production suppressants for Glaucoma

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 7, 2012, Pages 3733-3741

  Yang, Qiang ^a,b   Cho, Kin Sang ^b   Chen, Huihui ^b,c   Yu, Dekuang ^b,d   Wang, Wan Heng ^e   Luo, Gang ^b   Pang, Iok Hou ^e   Guo, Wenyi ^a,f   Chen, Dong Feng ^b,g  

^a FUDAN UNIVERSITY   (China)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e Glaucoma Research   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; BRINZOLAMIDE; LATANOPROST; PILOCARPINE; TIMOLOL MALEATE; ANTIHYPERTENSIVE AGENT; CARBONATE DEHYDRATASE INHIBITOR; MICROSPHERE; MUSCARINIC AGENT; PROSTAGLANDIN F; QUINOXALINE DERIVATIVE; SULFONAMIDE; THIAZINE DERIVATIVE; TIMOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS HUMOR OUTFLOW; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HISTOCHEMISTRY; HISTOLOGY; IMMUNOFLUORESCENCE TEST; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MOUSE; NERVE FIBER DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA GANGLION CELL; SINGLE DRUG DOSE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; ANIMAL; AQUEOUS HUMOR; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG SCREENING; FEASIBILITY STUDY; OPTIC NERVE; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; CARBONIC ANHYDRASE INHIBITORS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEASIBILITY STUDIES; INTRAOCULAR PRESSURE; MICE; MICE, INBRED C57BL; MICROSPHERES; MUSCARINIC AGONISTS; OCULAR HYPERTENSION; OPTIC NERVE; PILOCARPINE; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; RETINAL GANGLION CELLS; SULFONAMIDES; THIAZINES; TIMOLOL; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84865856806     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-9814     Document Type: Article

References (36)

1. Sappington RM, Carlson BJ, Crish SD, Calkins DJ. The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. Invest Ophthalmol Vis Sci. 2010;51:207-216.
2. Cone FE, Gelman SE, Son JL, Pease ME, Quigley HA. Differential susceptibility to experimental glaucoma among 3 mouse strains using bead and viscoelastic injection. Exp Eye Res. 2010;91:415-424.
3. Chen H, Wei X, Cho KS, et al. Optic neuropathy due to microbead-induced elevated intraocular pressure in the mouse. Invest Ophthalmol Vis Sci. 2011;52:36-44.
4. Wei X, Yu Z, Cho KS, et al. Neuroglobin is an endogenous neuroprotectant for retinal ganglion cells against glaucomatous damage. Am J Pathol. 2011;179:2788-2797.
5. Lindsey JD, Weinreb RN. Identification of the mouse uveoscleral outflow pathway using fluorescent dextran. Invest Ophthalmol Vis Sci. 2002;43:2201-2205.
6. Smith RS, Zabaleta A, Savinova OV, John SW. The mouse anterior chamber angle and trabecular meshwork develop without cell death. BMC Dev Biol. 2001;1:3.
7. Aihara M, Lindsey JD, Weinreb RN. Aqueous humor dynamics in mice. Invest Ophthalmol Vis Sci. 2003;44:5168-5173.
8. Aihara M, Lindsey JD, Weinreb RN. Effect on diurnal intraocular pressure variation of eliminating the alpha-2 adrenergic receptor subtypes in the mouse. Invest Ophthalmol Vis Sci. 2008;49:929-933.
9. Wollstein G, Schuman JS, Price LL, et al. Optical coherence tomography longitudinal evaluation of retinal nerve fiber layer thickness in glaucoma. Arch Ophthalmol. 2005;123:464-470.
10. Schuman JS, Hee MR, Arya AV, et al. Optical coherence tomography: a new tool for glaucoma diagnosis. Curr Opin Ophthalmol. 1995;6:89-95.
11. Pagliara MM, Lepore D, Balestrazzi E. The role of OCT in glaucoma management. Prog Brain Res. 2008;173:139-148.
12. Tan O, Chopra V, Lu AT, et al. Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology. 2009;116:2305-2314.
13. Strouthidis NG, Grimm J, Williams GA, Cull GA, Wilson DJ, Burgoyne CF. A comparison of optic nerve head morphology viewed by spectral domain optical coherence tomography and by serial histology. Invest Ophthalmol Vis Sci. 2010;51:1464-1474.
14. Camp AS, Ruggeri M, Munguba GC, et al. Structural correlation between the nerve fiber layer and retinal ganglion cell loss in mice with targeted disruption of the Brn3b gene. Invest Ophthalmol Vis Sci. 2011;52:5226-5232.
15. Nakano N, Hangai M, Nakanishi H, et al. Macular ganglion cell layer imaging in preperimetric glaucoma with speckle noisereduced spectral domain optical coherence tomography. Ophthalmology. 2011;118:2414-2426.
16. Gregory MS, Hackett CG, Abernathy EF, et al. Opposing roles for membrane bound and soluble Fas ligand in glaucomaassociated retinal ganglion cell death. PLoS One. 2011;6: e17659.
17. Pang I-H, Clark AF. IOP as a target-inflow and outflow pathways. In: Yorio T, Clark AF, Wax MB, eds. Ocular Therapeutics: An Eye on New Discoveries. New York, NY: Academic Press; 2008:45-67.
18. Liu G, Zeng T, Yu W, et al. Characterization of intraocular pressure responses of the Tibetan monkey (Macaca thibetana). Mol Vis. 2011;17:1405-1413.
19. Husain S, Whitlock NA, Rice DS, Crosson CE. Effects of latanoprost on rodent intraocular pressure. Exp Eye Res. 2006; 83:1453-1458.
20. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177-1185.
21. McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. Current management of glaucoma and the need for complete therapy. Am J Manag Care. 2008;14:S20-S27.
22. Wang X, Tay SS, Ng YK. An electron microscopic study of neuronal degeneration and glial cell reaction in the retina of glaucomatous rats. Histol Histopathol. 2002;17:1043-1052.
23. Kotera Y, Hangai M, Hirose F, Mori S, Yoshimura N. Threedimensional imaging of macular inner structures in glaucoma by using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2011;52:1412-1421.
24. Sriram P, Graham SL, Wang C, Yiannikas C, Garrick R, Klistorner A. Transsynaptic retinal degeneration in optic neuropathies: optical coherence tomography study. Invest Ophthalmol Vis Sci. 2012;53:1271-1275.
25. Spraul CW, Grossniklaus HE. Vitreous hemorrhage. Surv Ophthalmol. 1997;42:3-39.
26. Konstas AG, Hollo G, Astakhov YS, et al. Presentation and longterm follow-up of exfoliation glaucoma in Greece, Spain, Russia, and Hungary. Eur J Ophthalmol. 2006;16:60-66.
27. Konstas AG, Jay JL, Marshall GE, Lee WR. Prevalence, diagnostic features, and response to trabeculectomy in exfoliation glaucoma. Ophthalmology. 1993;100:619-627.
28. Ritch R, Schlotzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45:265-315.
29. Mitchell P, Wang JJ, Hourihan F. The relationship between glaucoma and pseudoexfoliation: the Blue Mountains Eye Study. Arch Ophthalmol. 1999;117:1319-1324.
30. Johnson TV, Fan S, Camras CB, Toris CB. Aqueous humor dynamics in exfoliation syndrome. Arch Ophthalmol. 2008; 126:914-920.
31. Campbell DG, Simmons RJ, Grant WM. Ghost cells as a cause of glaucoma. Am J Ophthalmol. 1976;81:441-450.
32. Liu L, Wu WC, Yeung L, et al. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging. 2010;41:72-77.
33. Akaishi T, Odani-Kawabata N, Ishida N, Nakamura M. Ocular hypotensive effects of anti-glaucoma agents in mice. J Ocul Pharmacol Ther. 2009;25:401-408.
34. Whitlock NA, McKnight B, Corcoran KN, Rodriguez LA, Rice DS. Increased intraocular pressure in mice treated with dexamethasone. Invest Ophthalmol Vis Sci. 2010;51:6496-6503.
35. Distelhorst JS, Hughes GM. Open-angle glaucoma. Am Fam Physician. 2003;67:1937-1944.
36. Camra CB. Prostaglandins. In: Ritch R, Shields B, Krupin T, eds. The Glaucomas: Glaucoma Therapy. Ann Arbor, MI: Mosby; 1996:1449-1461.